Results 291 to 300 of about 159,964 (350)
Some of the next articles are maybe not open access.
The Lancet, 2021
Biliary tract cancers, including intrahepatic, perihilar, and distal cholangiocarcinoma as well as gallbladder cancer, are low-incidence malignancies in most high-income countries, but represent a major health problem in endemic areas; moreover, the incidence of intrahepatic cholangiocarcinoma is rising globally. Surgery is the cornerstone of cure; the
Juan W, Valle +4 more
openaire +3 more sources
Biliary tract cancers, including intrahepatic, perihilar, and distal cholangiocarcinoma as well as gallbladder cancer, are low-incidence malignancies in most high-income countries, but represent a major health problem in endemic areas; moreover, the incidence of intrahepatic cholangiocarcinoma is rising globally. Surgery is the cornerstone of cure; the
Juan W, Valle +4 more
openaire +3 more sources
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
NEJM Evidence, 2022Durvalumab Combination for Biliary Tract CancerThis trial randomly assigned patients with previously untreated locally advanced or metastatic biliary tract cancer to receive durvalumab or placebo in combination with gemcitabine plus cisplatin.
D. Oh +28 more
semanticscholar +1 more source
Current Opinion in Gastroenterology, 1997
Cholangiocarcinomas are malignant tumors that arise from the epithelium of the intrahepatic or extrahepatic bile ducts. Cholangiocarcinomas are rare compared with hepatocellular carcinoma, comprising less than 10% of primary malignancies of the liver [1].
N Joseph Espat, Jean-Nicolas Vauthey
openaire +3 more sources
Cholangiocarcinomas are malignant tumors that arise from the epithelium of the intrahepatic or extrahepatic bile ducts. Cholangiocarcinomas are rare compared with hepatocellular carcinoma, comprising less than 10% of primary malignancies of the liver [1].
N Joseph Espat, Jean-Nicolas Vauthey
openaire +3 more sources
Current Opinion in Gastroenterology, 2001
Advances in cellular and molecular biology of extrahepatic cholangiocarcinoma and gallbladder adenocarcinoma are providing innovative means for the diagnosis and treatment of biliary tract cancer. Similarly, refinements in noninvasive studies--including helical computed tomography, magnetic resonance cholangiopancreatography, and endoscopic ...
E K, Abdalla, J N, Vauthey
openaire +4 more sources
Advances in cellular and molecular biology of extrahepatic cholangiocarcinoma and gallbladder adenocarcinoma are providing innovative means for the diagnosis and treatment of biliary tract cancer. Similarly, refinements in noninvasive studies--including helical computed tomography, magnetic resonance cholangiopancreatography, and endoscopic ...
E K, Abdalla, J N, Vauthey
openaire +4 more sources
Current Opinion in Gastroenterology, 2000
Investigation into the molecular and cellular biology of carcinogenesis continues to elucidate potential mechanisms for the initiation and progression of biliary tract cancer. The potential role of cell cycle regulators, such as Fas ligand, has been examined in the etiology of bile duct carcinoma.
J N, Cormier, J N, Vauthey
openaire +2 more sources
Investigation into the molecular and cellular biology of carcinogenesis continues to elucidate potential mechanisms for the initiation and progression of biliary tract cancer. The potential role of cell cycle regulators, such as Fas ligand, has been examined in the etiology of bile duct carcinoma.
J N, Cormier, J N, Vauthey
openaire +2 more sources
Current Opinion in Gastroenterology, 1999
Recent advances in the molecular and cellular biology, diagnosis, and treatment of biliary tract cancer are reviewed. Several studies have delineated the molecular and cellular biology of cholangiocarcinoma and gallbladder carcinoma. Hepatocyte growth factor seems to be mitogenic to gallbladder carcinoma, and its inhibition may have a therapeutic role ...
J A, Ehrenfried, J N, Vauthey
openaire +2 more sources
Recent advances in the molecular and cellular biology, diagnosis, and treatment of biliary tract cancer are reviewed. Several studies have delineated the molecular and cellular biology of cholangiocarcinoma and gallbladder carcinoma. Hepatocyte growth factor seems to be mitogenic to gallbladder carcinoma, and its inhibition may have a therapeutic role ...
J A, Ehrenfried, J N, Vauthey
openaire +2 more sources
New England Journal of Medicine, 1999
In the United States, an estimated 20,000 new cases of liver and biliary tract cancer are diagnosed annually.1 Biliary tract cancer is the second most common primary hepatobiliary cancer, after hepatocellular cancer. Approximately 7500 new cases of biliary tract cancer are diagnosed per year; about 5000 of these are gallbladder cancer, and between 2000
P C, de Groen +4 more
openaire +2 more sources
In the United States, an estimated 20,000 new cases of liver and biliary tract cancer are diagnosed annually.1 Biliary tract cancer is the second most common primary hepatobiliary cancer, after hepatocellular cancer. Approximately 7500 new cases of biliary tract cancer are diagnosed per year; about 5000 of these are gallbladder cancer, and between 2000
P C, de Groen +4 more
openaire +2 more sources
Precision Medicine in Biliary Tract Cancer.
Journal of Clinical Oncology, 2022Precision medicine has become a dominant theme in the treatment of biliary tract cancers (BTCs). Although prognosis remains poor, technologies for improved molecular characterization along with the US Food and Drug Administration approval of several ...
A. Scott, R. Sharman, R. Shroff
semanticscholar +1 more source
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Expert Opinion on Investigational Drugs, 2021Introduction: The prognosis of patients with advanced biliary tract cancer (BTC) remains dismal, with a 5-year overall survival rate of less than 10%.
A. Rizzo, A. Ricci, G. Brandi
semanticscholar +1 more source
Advanced Biliary Tract Cancers
American Society of Clinical Oncology Educational Book, 2012Overview: Single-agent management of metastatic biliary tract cancers with 5-fluorouracil (5-FU) or gemcitabine has shown limited efficacy, although 5-FU has been shown to be more effective than best supportive care alone. An analysis of phase II trials has suggested that platinums enhanced the efficacy of single-agent fluoropyrimidines. In a phase III
Laura Williams, Goff, Jordan D, Berlin
openaire +2 more sources